NLRP3炎症小体在肝脏疾病发病中的作用研究进展*

doi:10.3969/j.issn.1672-5069.2014.05.029

Abstract

Abstract: The inflammasome is a sort of multiprotein complexes in the cytoplasm,acting as an important component of the body’s innate immune. The nucleotide-binding oligomerization domain（NOD）-like receptors（NLRs）,for example the NLRP3,mainly consists of NLRP3,apoptosis-associated speck-like protein（ASC）and cysteinyl aspartate specific proteinase （Caspase-1）,which plays a vital roles in the immune regulation and antimicrobial activities. In recent years,there has been a growing number of evidence indicating that NLRP3,the inflammasome,may be closely associated with all kinds of liver diseases. The activation pathway,regulatory mechanism of NLRP3 and its relationship with liver diseases were reviewed .

Key words: Liver diseases, Inflammasome, NLRP3

Wang Xiaotong, Han Tao. What roles the NLRP3 play in liver diseases[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2014, 17(5): 546-549.

References

[1] Martinon F,Burns K,Tschopp J. The inflammasome:a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell,2002,10（2）:417-426.
[2] 雷国伟,毛立明,李华,等. 炎症小体在对抗微生物感染中的作用. 中国细胞生物学学报,2011,32（12）:1301-1315.
[3] Schroder K,Tschopp J. The inflammasomes. Cell,2010,140（6）:821-832.
[4] Muruve D A,Petrilli V,Zaiss A K,et al. The inflammasome recognizes cytosolic microbial and host DNA and triggers an innate immune response. Nature,2008,452（7183）:103-107.
[5] Hornung V,Bauernfeind F,Halle A,et al. Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nat Immunol,2008,9（8）:847-856.
[6] Zhou R,Tardivel A,Thorens B,et al. Thioredoxin-interacting protein links oxidative stress to inflammasome activation. Nat Immunol,2010,11（2）:136-140.
[7] Martinon F. Detection of immune danger signals by NALP3. J Leukoc Biol,2008,83（3）:507-511.
[8] Mayor A,Martinon F,De Smedt T,et al. A crucial function of SGT1 and HSP90 in inflammasome activity links mammalian and plant innate immune responses. Nat Immunol,2007,8（5）:497-503.
[9] Mariathasan S. ASC,Ipaf and Cryopyrin/Nalp3:bona fide intracellular adapters of the caspase-1 inflammasome. Microbes Infect,2007,9（5）:664-671.
[10] Anderson J P,Mueller J L,Rosengren S,et al. Structural, expression,and evolutionary analysis of mouse CIAS1. Gene, 2004,338（1）:25-34.
[11] Lech M,Avila-Ferrufino A,Skuginna V,et al. Quantitative expression of RIG-like helicase,NOD-like receptor and inflammasome-related mRNAs in humans and mice. Int Immunol, 2010,22（9）:717-728.
[12] Boaru S G,Borkham-Kamphorst E,Tihaa L,et al. Expression analysis of inflammasomes in experimental models of inflammatory and fibrotic liver disease. J Inflamm （Lond）,2012,9（1）:49.
[13] Chen S,Sun B. Negative regulation of NLRP3 inflammasome signaling. Protein Cell,2013,4（4）:251-258.
[14] Saitoh T,Fujita N,Jang M H,et al. Loss of the autophagy protein Atg16L1 enhances endotoxin-induced IL-1beta production. Nature,2008,456（7219）:264-268.
[15] Guarda G,Braun M,Staehli F,et al. Type I interferon inhibits interleukin-1 production and inflammasome activation. Immunity,2011,34（2）:213-223.
[16] Guarda G,Dostert C,Staehli F,et al. T cells dampen innate immune responses through inhibition of NLRP1 and NLRP3 inflammasomes. Nature,2009,460（7252）:269-273.
[17] Chae JJ,Cho YH,Lee GS,et al. Gain-of-function Pyrin mutations induce NLRP3 protein-independent interleukin-1beta activation and severe autoinflammation in mice. Immunity,2011,34（5）:755-768.
[18] Bauernfeind F,Rieger A,Schildberg F A,et al. NLRP3 inflammasome activity is negatively controlled by miR-223. J Immunol,2012,189（8）:4175-4181.
[19] Haneklaus M,Gerlic M,Kurowska-Stolarska M,et al. Cutting edge:miR-223 and EBV miR-BART15 regulate the NLRP3 inflammasome and IL-1beta production. J Immunol,2012,189（8）:3795-3799.
[20] Burdette D,Haskett A,Presser L,et al. Hepatitis C virus activates interleukin-1beta via caspase-1 -inflammasome complex. J Gen Virol,2012,93（Pt 2）:235-246.
[21] Csak T,Ganz M,Pespisa J,et al. Fatty acid and endotoxin activate inflammasomes in mouse hepatocytes that release danger signals to stimulate immune cells. Hepatology,2011,54（1）:133-144.
[22] Negash A A,Ramos H J,Crochet N,et al. IL-1beta production through the NLRP3 inflammasome by hepatic macrophages links hepatitis C virus infection with liver inflammation and disease. PLoS Pathog,2013,9（4）:e1003330.
[23] Manigold T,Bocker U,Chen J,et al. Hepatitis B core antigen is a potent inductor of interleukin-18 in peripheral blood mononuclear cells of healthy controls and patients with hepatitis B infection. J Med Virol,2003,71（1）:31-40.
[24] Paik Y H,Lee K S,Lee H J,et al. Hepatic stellate cells primed with cytokines upregulate inflammation in response to peptidoglycan or lipoteichoic acid. Lab Invest,2006,86（7）:676-686.
[25] Watanabe A,Sohail M A,Gomes D A,et al. Inflammasome-mediated regulation of hepatic stellate cells. Am J Physiol Gastrointest Liver Physiol,2009,296（6）:G1248-G1257.
[26] Kolb R,Liu G H,Janowski A M,et al. Inflammasomes in cancer:a double-edged sword. Protein Cell,2014,5（1）:12-20.
[27] Huber S,Gaglian N,Zenewicz L A,et al. IL-22BP is regulated by the inflammasome and modulates tumorigenesis in the intestine.Nature,2012,419（7423）:259-263.
[28] Sakurai T,He G,Matsuzawa A,et al. Hepatocyte necrosis induced by oxidative stress and IL-1 alpha release mediate carcinogen-induced compensatory proliferation and liver tumorigenesis. Cancer Cell,2008,14（2）:156-165.
[29] Dinarello C A. Why not treat human cancer with interleukin-1 blockade. Cancer Metastasis Rev,2010,29（2）:317-329.
[30] Vidal-Vanaclocha F,Fantuzzi G,Mendoza L,et al. IL-18 regulates IL-1beta-dependent hepatic melanoma metastasis via vascular cell adhesion molecule-1. Proc Natl Acad Sci USA,2000,97（2）: 734-739.
[31] Diao L,Marshall A H,Dai X,et al. Burn plus lipopolysaccharide augments endoplasmic reticulum stress and NLRP3 inflammasome activation and reduces PGC-1alpha in liver. Shock,2014,41（2）:138-144.
[32] Martin-Murphy B V,Holt M P,Ju C. The role of damage associated molecular pattern molecules in acetaminophen-induced liver injury in mice. Toxicol Lett,2010,192（3）:387-394.
[33] Imaeda A B,Watanabe A,Sohail M A,et al. Acetaminophen-induced hepatotoxicity in mice is dependent on Tlr9 and the Nalp3 inflammasome. J Clin Invest,2009,119（2）:305-314.
[34] Ganz M,Csak T,Nath B,et al. Lipopolysaccharide induces and activates the Nalp3 inflammasome in the liver. World J Gastroenterol,2011,17（43）:4772-4778.
[35] Zhu P,Duan L,Chen J,et al. Gene silencing of NALP3 protects against liver ischemia-reperfusion injury in mice. Hum Gene Ther,2011,22（7）:853-864.
[36] Hsiang C Y,Wu S L,Cheng S E,et al. Acetaldehyde-induced interleukin-1beta and tumor necrosis factor-alpha production is inhibited by berberine through nuclear factor-kappaB signaling pathway in HepG2 cells. J Biomed Sci,2005,12（5）:791-801.
[37] Desantis D A,Ko C W,Liu Y,et al. Alcohol-induced liver injury is modulated by Nlrp3 and Nlrc4 inflammasomes in mice. Mediators Inflamm,2013,2013:751374.

What roles the NLRP3 play in liver diseases

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Lu Lungen. Cholestatic liver diseases：What we know and how to deal with [J]. Journal of Practical Hepatology, 2019, 22(5): 754-757.
[2]	Hong Jia, Wu Xiaoning, You Hong. Standardized diagnosis of cholestatic liver diseases [J]. Journal of Practical Hepatology, 2019, 22(5): 758-760.
[3]	Wang Haifang, Yang Dawei, Jia Bei. Impact of nutrition support and medusa administration on liver function, erythrocyte and platelet parameters in patients with alcoholic liver diseases [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(3): 381-384.
[4]	Cui Qinghua, Tao Hong, Wang Xiaoyue, et al.. Changes of serum glycosylated hemoglobin level and cardiac functions in patients with non-alcoholic fatty liver disease [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 69-72.
[5]	Zhong Yan, Su Shuting, Mi Yuqiang.. Treatment of patients with nonalcoholic fatty liver disease [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 145-148.
[6]	Dong Xuelian, Zhang Wenjun.. Application of controlled attenuation parameter in screening individuals with risk of metabolic syndrome [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 868-871.
[7]	Huang Faguang, Li Xiaocheng, Gong Jianping, et al.. Research on insulin resistance related protein molecules in human liver tissues by comprehensive gene expression profiling analysis [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 872-876.
[8]	Guo Baona, Zhan Yutao.. Clinical features of alcoholic liver diseases:An analysis of 79 cases [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 877-880.
[9]	Pu Yonglan, Chen Yuanwen, Fan Jiangao.. Gluten intestinal disease and nonalcoholic fatty liver: One case report [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 981-982.
[10]	Gao Miaomiao, Zhang Jiyuan, Zou Zhengsheng.. Myeloid-derived suppressor cells in the pathogenesis of liver diseases [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(5): 813-816.
[11]	Wang Dengbin. Progress of imaging technologies for diagnosis of liver diseases [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(4): 489-492.
[12]	Liu Yanghe, Long Dengyi, Bei Zheng, et al. Efficacy of bacillus subtilis duplex and polyene phosphatidylcholine combination in treatments of patients with nonalcoholic fatty liver diseases [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(4): 573-576.
[13]	Yang Huimin, Jiang Chunyan. Clinical efficacy of herbal medicine and silibinin in the treatment of patients with nonalcoholic fatty liver diseases [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(3): 467-468.
[14]	Zeng Minde. Mechanisms of lipotoxicity in pathogenesis of nonalcoholic fatty liver diseases [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(2): 153-156.
[15]	Zhang Zhihua, Gu Tianyi, Chen Liuying, et al. Meta analysis of efficacy of ornithine aspartate in the treatment of patients with fatty liver [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(2): 233-236.